Skip to main content

Prevalence and safety of diazoxide in the neonatal intensive care unit.

Publication ,  Journal Article
Gray, KD; Dudash, K; Escobar, C; Freel, C; Harrison, T; McMillan, C; Puia-Dumitrescu, M; Cotten, CM; Benjamin, R; Clark, RH; Benjamin, DK ...
Published in: J Perinatol
November 2018

OBJECTIVE: Diazoxide is used to treat infants with persistent hypoglycemia, but the prevalence of its use and adverse effects are not well described. We report demographic and clinical characteristics of infants treated with diazoxide in neonatal intensive care units (NICUs). STUDY DESIGN: Retrospective cohort study of infants 24-41 weeks' gestation admitted to 392 NICUs from 1997-2016, comparing characteristics between hypoglycemic infants exposed/not exposed to diazoxide. For diazoxide courses > 1 day, we report percentages of infants starting diuretics and/or developing new ventilator/oxygen requirement during therapy. RESULTS: Among 1,249,466 infants, 185,832 had hypoglycemia; 1066/185,832 (0.57%) received diazoxide. Diazoxide use increased over time (P = 0.001). Infants receiving diazoxide varied from 0-14.9% among centers. New diuretic courses were associated with 91/664 (14%), and new oxygen or ventilator requirement during therapy was associated with 64/556 (12%) and 34/647 (5%), respectively. CONCLUSIONS: Diazoxide use in NICU settings has increased over time. Infants receiving diazoxide commonly received diuretics.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Perinatol

DOI

EISSN

1476-5543

Publication Date

November 2018

Volume

38

Issue

11

Start / End Page

1496 / 1502

Location

United States

Related Subject Headings

  • United States
  • Retrospective Studies
  • Prevalence
  • Pediatrics
  • Male
  • Intensive Care Units, Neonatal
  • Infant, Newborn
  • Hypoglycemia
  • Humans
  • Gestational Age
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gray, K. D., Dudash, K., Escobar, C., Freel, C., Harrison, T., McMillan, C., … Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee, . (2018). Prevalence and safety of diazoxide in the neonatal intensive care unit. J Perinatol, 38(11), 1496–1502. https://doi.org/10.1038/s41372-018-0218-4
Gray, Keyaria D., Kathryn Dudash, Carla Escobar, Colman Freel, Tylah Harrison, Chandler McMillan, Mihai Puia-Dumitrescu, et al. “Prevalence and safety of diazoxide in the neonatal intensive care unit.J Perinatol 38, no. 11 (November 2018): 1496–1502. https://doi.org/10.1038/s41372-018-0218-4.
Gray KD, Dudash K, Escobar C, Freel C, Harrison T, McMillan C, et al. Prevalence and safety of diazoxide in the neonatal intensive care unit. J Perinatol. 2018 Nov;38(11):1496–502.
Gray, Keyaria D., et al. “Prevalence and safety of diazoxide in the neonatal intensive care unit.J Perinatol, vol. 38, no. 11, Nov. 2018, pp. 1496–502. Pubmed, doi:10.1038/s41372-018-0218-4.
Gray KD, Dudash K, Escobar C, Freel C, Harrison T, McMillan C, Puia-Dumitrescu M, Cotten CM, Benjamin R, Clark RH, Benjamin DK, Greenberg RG, Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee. Prevalence and safety of diazoxide in the neonatal intensive care unit. J Perinatol. 2018 Nov;38(11):1496–1502.

Published In

J Perinatol

DOI

EISSN

1476-5543

Publication Date

November 2018

Volume

38

Issue

11

Start / End Page

1496 / 1502

Location

United States

Related Subject Headings

  • United States
  • Retrospective Studies
  • Prevalence
  • Pediatrics
  • Male
  • Intensive Care Units, Neonatal
  • Infant, Newborn
  • Hypoglycemia
  • Humans
  • Gestational Age